Two-year data from the SPIRIT III trial, Abbott’s U.S. pivotal trial,demonstrated that its Xience V everolimus-eluting coronary stent systemcontinues to deliver clinically superior benefits compared to BostonScientific’s Taxus paclitaxel-eluting coronary stent system, accordingto a presentation at a late-breaking clinical trials session at EuroPCR2008 in Barcelona, Spain.